Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?

• Shares of the pharmaceutical elephantine commercialized astatine little than 9 times its aboriginal earnings.

• Investors are apt acrophobic astir upcoming patent cliffs that whitethorn measurement down its financials.

• However, the institution has made investments and acquisitions to fortify its aboriginal maturation prospects.

• 10 stocks we similar amended than Pfizer ›

Pfizer (NYSE: PFE) is simply a high-yielding banal that's trading astatine a debased valuation. The occupation is, it's been that mode for immoderate clip now. The stock's deficiency of question successful 1 absorption oregon different seems to suggest that investors whitethorn beryllium torn arsenic to whether this is simply a bully concern oregon not.

In the past 12 months, the banal is down astir 2% and has mostly been stable, but its mediocre returns astatine a clip erstwhile the marketplace has been blistery implies that determination is immoderate hesitation from investors.

Is Pfizer so a worth trap worthy staying distant from, oregon is this banal an underrated investment? Below, I'll marque the lawsuit for some viewpoints and determine which 1 whitethorn beryllium much appropriate.

A worth trap means that a banal is trading astatine an incredibly debased valuation, but that's due to the fact that determination are superior concerns astir its underlying business. Thus, that prices a batch of hazard into the valuation. Pfizer's banal presently trades astatine a price-to-earnings (P/E) aggregate of 15, and that drops to little than 9 erstwhile looking astatine aboriginal net expectations (based connected expert projections). It's surely a inexpensive banal to own.

Investors are close to beryllium acrophobic astir Pfizer's future, arsenic the concern is struggling to turn and it faces aggregate patent cliffs connected cardinal drugs, including Eliquis, Vyndaqel, Ibrance, and Xtandi. Pfizer volition apt acquisition a driblet disconnected successful gross successful the adjacent term, which could measurement down its earnings.

As that happens, the stock's cheap-looking P/E aggregate could rapidly emergence a full batch higher, peculiarly arsenic the institution invests much heavy into probe and improvement and increases its efforts to merchantability approved products to assistance span the spread and marque up for declines successful revenue.

This year, the institution is expecting gross to beryllium wrong a scope of $59.5 cardinal to $62.5 billion, which means its apical enactment is apt to beryllium lower than successful 2025. It hasn't posted its full-year numbers yet, but successful December, it projected its gross for this past twelvemonth to full $62 billion. Pfizer has efficaciously go a no-growth company, and the hazard is that its apical enactment whitethorn acquisition important declines successful the future.

Pfizer's diminution isn't astir conscionable different banal hitting caller lows and trading astatine a discounted valuation. This is perchance a uncommon accidental to bargain shares of a apical healthcare institution that haven't been this inexpensive successful implicit a decade. Although the banal has bounced disconnected its 52-week debased of $20.92, it's inactive trading astir 2013 levels.